Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome

References

• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Kipps TJ, Stevenson FK, Wu CJ, et al. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017;3:16096.
   PubMed Web of Science ®Google Scholar
• Fabbri G, Dalla-Favera R. The molecular pathogenesis of chronic lymphocytic leukaemia. Nat Rev Cancer. 2016;16:145–162.
   PubMed Web of Science ®Google Scholar
• Packham G, Stevenson FK. Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. Immunology. 2005;114:441–449.
   PubMed Web of Science ®Google Scholar
• Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840–1847.
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848–1854.
   PubMed Web of Science ®Google Scholar
• Mertens D, Stilgenbauer S. Prognostic and predictive factors in patients with chronic lymphocytic leukemia: relevant in the era of novel treatment approaches? JCO. 2014;32:869–872.
   PubMed Web of Science ®Google Scholar
• Rigolin GM, Saccenti E, Bassi C, et al. Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations. J Hematol Oncol. 2016;9:88.
   PubMed Web of Science ®Google Scholar
• Ramsay AJ, Quesada V, Foronda M, et al. POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia. Nat Genet. 2013;45:526–530.
   PubMed Web of Science ®Google Scholar
• Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015;526:525–530.
   PubMed Web of Science ®Google Scholar
• Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475:101–105.
   PubMed Web of Science ®Google Scholar
• Lin TT, Norris K, Heppel NH, et al. Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. Br J Haematol. 2014;167:214–223.
   PubMed Web of Science ®Google Scholar
• Grabowski P, Hultdin M, Karlsson K, et al. Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status. Blood. 2005;105:4807–4812.
   PubMed Web of Science ®Google Scholar
• Rampazzo E, Bonaldi L, Trentin L, et al. Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes. Haematologica. 2012;97:56–63.
   PubMed Web of Science ®Google Scholar
• Mansouri L, Grabowski P, Degerman S, et al. Short telomere length is associated with NOTCH1/SF3B1/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients. Am J Hematol. 2013;88:647–651.
   PubMed Web of Science ®Google Scholar
• Damle RN, Batliwalla FM, Ghiotto F, et al. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. Blood. 2004;103:375–382.
   PubMed Web of Science ®Google Scholar
• Roos G, Krober A, Grabowski P, et al. Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. Blood. 2008;111:2246–2252.
   PubMed Web of Science ®Google Scholar
• Gilley D, Blackburn EH. Lack of telomere shortening during senescence in Paramecium. Proc Natl Acad Sci USA. 1994;91:1955–1958.
   PubMed Web of Science ®Google Scholar
• Blackburn EH. Telomeres. Trends Biochem Sci. 1991;16:378–381.
   PubMed Web of Science ®Google Scholar
• Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature. 1990;345:458–460.
   PubMed Web of Science ®Google Scholar
• Lansdorp PM, Verwoerd NP, van de Rijke FM, et al. Heterogeneity in telomere length of human chromosomes. Hum Mol Genet. 1996;5:685–691.
   PubMed Web of Science ®Google Scholar
• Verfaillie CM, Pera MF, Lansdorp PM. Stem cells: hype and reality. Hematology Am Soc Hematol Educ Program. 2002;2002:369–391.
   Google Scholar
• Dos Santos P, Panero J, Palau Nagore V, et al. Telomere shortening associated with increased genomic complexity in chronic lymphocytic leukemia. Tumor Biol. 2015;36:8317–8324.
   PubMedGoogle Scholar
• Strefford JC, Kadalayil L, Forster J, et al. Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial. Leukemia. 2015;29:2411–2414.
   PubMed Web of Science ®Google Scholar
• Thomay K, Fedder C, Hofmann W, et al. Telomere shortening, TP53 mutations and deletions in chronic lymphocytic leukemia result in increased chromosomal instability and breakpoint clustering in heterochromatic regions. Ann Hematol. 2017;96:1493–1500.
   PubMed Web of Science ®Google Scholar
• Stephens PJ, Greenman CD, Fu B, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell. 2011;144:27–40.
   PubMed Web of Science ®Google Scholar
• Rode A, Maass KK, Willmund KV, et al. Chromothripsis in cancer cells: an update. Int J Cancer. 2016;138:2322–2333.
   PubMed Web of Science ®Google Scholar
• Maciejowski J, Lange T. Telomeres in cancer: tumour suppression and genome instability. Nat Rev Mol Cell Biol. 2017;18:175–186.
   PubMed Web of Science ®Google Scholar
• Zhang CZ, Spektor A, Cornils H, et al. Chromothripsis from DNA damage in micronuclei. Nature. 2015;522:179–184.
   PubMed Web of Science ®Google Scholar
• Crasta K, Ganem NJ, Dagher R, et al. DNA breaks and chromosome pulverization from errors in mitosis. Nature. 2012;482:53–58.
   PubMed Web of Science ®Google Scholar
• Herling CD, Klaumunzer M, Rocha CK, et al. Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy. Blood. 2016;128:395–404.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Cymbalista F, Leblond V, et al. Alemtuzumab combined with dexamethasone, followed by alemtuzumab maintenance or Allo-SCT in “ultra High-risk” CLL: final results from the CLL2O phase II study. Blood. 2014;124:1991.
   Web of Science ®Google Scholar
• Jebaraj BMC, Kienle D, Lechel A, et al. Telomere length in mantle cell lymphoma. Blood. 2013;121:1184–1187.
   PubMed Web of Science ®Google Scholar
• O'Callaghan N, Dhillon V, Thomas P, et al. A quantitative real-time PCR method for absolute telomere length. Biotechniques. 2008;44:807–809.
   PubMed Web of Science ®Google Scholar
• Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res. 2002;30:e47.
   PubMed Web of Science ®Google Scholar
• Jebaraj BCM, Busch R, Zenz T, et al. Telomere length and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2013;122:671.
   Web of Science ®Google Scholar
• Krober A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100:1410–1416.
   PubMed Web of Science ®Google Scholar
• Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–1916.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Schnaiter A, Paschka P, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014;123:3247–3254.
   PubMed Web of Science ®Google Scholar
• Edelmann J, Holzmann K, Miller F, et al. High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood. 2012;120:4783–4794.
   PubMed Web of Science ®Google Scholar
• Noël J-F, Wellinger RJ. Abrupt telomere losses and reduced end-resection can explain accelerated senescence of Smc5/6 mutants lacking telomerase. DNA Repair (Amst). 2011;10:271–282.
   PubMed Web of Science ®Google Scholar
• Potts PR, Yu H. The SMC5/6 complex maintains telomere length in ALT cancer cells through SUMOylation of telomere-binding proteins. Nat Struct Mol Biol. 2007;14:581–590.
   PubMed Web of Science ®Google Scholar
• Moradi-Fard S, Sarthi J, Tittel-Elmer M, et al. Smc5/6 is a telomere-associated complex that regulates Sir4 binding and TPE. PLoS Genet. 2016;12:e1006268.
   PubMed Web of Science ®Google Scholar
• Deng Y, Chan S, Chang S. Telomere dysfunction and tumor suppression-the senescence connection. Nat Rev Cancer. 2008;8:450–458.
   PubMed Web of Science ®Google Scholar
• Brugat T, Gault N, Baccelli I, et al. Aberrant telomere structure is characteristic of resistant chronic lymphocytic leukaemia cells. Leukemia. 2009;24:246–251.
   PubMed Web of Science ®Google Scholar
• Salin H, Ricoul M, Morat L, et al. Increased genomic alteration complexity and telomere shortening in B-CLL cells resistant to radiation-induced apoptosis. Cytogenet Genome Res. 2008;122:343–349.
   PubMed Web of Science ®Google Scholar
• Lee JJ, Nam CE, Cho SH, et al. Telomere length shortening in non-Hodgkin’s lymphoma patients undergoing chemotherapy. Ann Hematol. 2003;82:492–495.
   PubMed Web of Science ®Google Scholar
• Arnoult N, Karlseder J. Complex interactions between the DNA-damage response and mammalian telomeres. Nat Struct Mol Biol. 2015;22:859–866.
   PubMed Web of Science ®Google Scholar
• Guièze R, Pages M, Véronèse L, et al. Telomere status in chronic lymphocytic leukemia with TP53 disruption. Oncotarget. 2016;7:56976–56985.
   PubMed Web of Science ®Google Scholar
• Scheffold A, Jebaraj BMC, Jaramillo S, et al. Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial. Br J Haematol. 2016;179:342–346.
   PubMed Web of Science ®Google Scholar
• Schnaiter A, Paschka P, Rossi M, et al. NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. Blood. 2013;122:1266–1270.
   PubMed Web of Science ®Google Scholar